Real-life Data for Tenofovir Alafenamide Fumarate Treatment of Hepatitis B: the Pythagoras Cohort

Basit Öğe Kaydı
dc.authoridKARASAHİN, Omer/0000-0002-4245-1534
dc.authoridmete, ayşe özlem/0000-0003-0994-4465
dc.authoridtoplu, sibel altunışık/0000-0002-2915-4666
dc.authoridÖren, Meryem Merve/0000-0002-3383-7830
dc.authoridKalkan, İrem Akdemir/0000-0001-5136-9148;
dc.authorwosidyıldız, yeşim/AAD-2219-2022
dc.authorwosidTaşova, Yeşim/JVY-8831-2024
dc.authorwosidKaya, Safak/N-1419-2014
dc.authorwosidAkgul, Fethiye/GYU-0934-2022
dc.authorwosidKARASAHİN, Omer/AAM-8456-2021
dc.authorwosidmete, ayşe özlem/AAA-5072-2021
dc.authorwosidtoplu, sibel altunışık/ABH-5816-2020
dc.contributor.authorKarasahin, Omer
dc.contributor.authorKalkan, Irem Akdemir
dc.contributor.authorDal, Tuba
dc.contributor.authorToplu, Sibel Altunisik
dc.contributor.authorHarputoglu, Murat
dc.contributor.authorMete, Ayse Ozlem
dc.contributor.authorKomur, Suheyla
dc.date.accessioned2024-08-04T20:50:13Z
dc.date.available2024-08-04T20:50:13Z
dc.date.issued2021
dc.departmentİnönü Üniversitesien_US
dc.description.abstractBackground: Chronic hepatitis B (CHB) is a viral infection that can result in life-threatening conditions, such as hepatocellular carcinoma and cirrhosis. Tenofovir, which is used for the treatment of CHB, is a nucleotide analog that inhibits HBV-DNApolymerase and has two formulations: disoproxil and alafenamide. In contrast to tenofovir disoproxil fumarate (TDF), tenofovir alafenamide fumarate (TAF) penetrates the whole hepatocyte without being eliminated due to its longer plasma half-life and greater plasma stability. As a result, side effects such as proximal renal tubulopathy and loss of bone density are less common in the treatment of TAF and have similar efficacy to TDF. Objectives: The purpose of the study was to evaluate the effectiveness and reliability of TAF using real-life data. Methods: This retrospective cohort study was carried out in secondary or tertiary healthcare centers in southern Turkey. A total of 480 patients aged 18 years and older were administered TAF for an appropriate indication by the infectious diseases and gastroenterology clinics of the healthcare centers participating in this study. The data collected at t = 0, t =3, and t = 6 months of treatment were analyzed. The chi-square, Mann-Whitney U, Friedman, Wilcoxon, Cochran's Q, and McNemar's tests were used. Results: The mean age of the patients was 47.40 +/- 14.5, and 327 of them (68.1%) were male. A total of 78.1% of the 480 patients who underwent the TAF treatment had previous antiviral therapy experience (TDF, n =340; 70.8 %), and 21.9% were treatment-naive. The most common reasons for the initiation of TAF treatment were the use of drugs affecting bone mineral density (BMD) (42.9%) and osteoporosis (22.3%). Patients who had taken TDF experienced a significant improvement in glomerular filtration rate (GFR), hip and spine T-scores, and phosphorus levels from t = 0 months tot = 6 months after switching to TAF (P < 0.05). For this group, no statistically significant difference was observed concerning LDL and cholesterol levels from t= 0 months to t = 6 months. Side effects were reported by 5.7% of patients in the third month and 7.1% in the sixth month, with the most common side effect being hair loss (1%). Conclusions: TAF was found to be an effective and safe alternative to TDF with lower incidences of its long-term effects, such as nephrotoxicity and decreased bone density.en_US
dc.identifier.doi10.5812/hepatmon.104943
dc.identifier.issn1735-143X
dc.identifier.issn1735-3408
dc.identifier.issue2en_US
dc.identifier.scopus2-s2.0-85105532673en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.urihttps://doi.org/10.5812/hepatmon.104943
dc.identifier.urihttps://hdl.handle.net/11616/99916
dc.identifier.volume21en_US
dc.identifier.wosWOS:000635211600001en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherBrieflanden_US
dc.relation.ispartofHepatitis Monthlyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBone Mineral Densityen_US
dc.subjectHepatitis Ben_US
dc.subjectChronic Hepatitis Ben_US
dc.subjectGlomerular Filtration Rateen_US
dc.subjectTenofovir Alafenamideen_US
dc.subjectReal Lifeen_US
dc.subjectTenofovir Disoproxilen_US
dc.titleReal-life Data for Tenofovir Alafenamide Fumarate Treatment of Hepatitis B: the Pythagoras Cohorten_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu